ArticlemedRxiv : the preprint server for health sciences2026
Using human genetics to understand the effect of modulating targets of antihypertensive drugs in pregnancy.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Background and Aims: Hypertension during pregnancy is a major cause of maternal and neonatal morbidity and mortality, yet the efficacy and safety of antihypertensive treatments in this setting remain uncertain. We evaluated the effects of antihypertensive drug targets on adverse pregnancy-related outcomes using genetic variants to instrument target perturbation. Methods: We performed drug target Mendelian randomization to mimic pharmacological perturbation of targets from six commonly used antihypertensive drug classes, using data from up to 671,922 pregnant women. Genetic variants near drug target genes associated with systolic or diastolic blood pressure were selected as instruments. We estimated effects of target modulation on six primary and eight secondary pregnancy outcomes. Results: Genetically instrumented downregulation of blood pressure through β-blocker (BB) and calcium-channel blocker (CCB) targets, particularly ADRB1 and CACNB2, was associated with a reduced risk of hypertensive disorders of pregnancy, including preeclampsia. For example, CACNB2-instrumented lowering corresponded to a 7% (95% CI: 5-9%) reduction in preeclampsia risk per 1 mmHg decrease in blood pressure. For most of the other targets, estimates were directionally consistent but imprecise. Across additional outcomes, effects varied by target, with suggestive evidence for reduced risks of miscarriage, preterm birth, small-for-gestational age birth, and labour induction, although these estimates were accompanied by substantial uncertainty. Conclusions: These findings support a protective effect of BB and CCB targets on hypertensive disorders of pregnancy and highlight potential target-specific differences in safety. This work illustrates the value of Mendelian randomization in addressing clinical uncertainties where robust trial evidence is limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.